Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

20141,700 citationsJournal Articlebronze Open Access

Authors

Nezam H. Afdhal · Hadassah Medical Center

Stefan Zeuzem · Goethe University Frankfurt

Paul Y. Kwo · Indiana University School of Medicine

Mario Chojkier · University of California San Diego Medical Center

Norman Gitlin · Atlanta Gastroenterology Associates

Massimo Puoti · Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Manuel Romero‐Gómez

Abstract

Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection. (Funded by Gilead Sciences; ION-1 ClinicalTrials.gov number NCT01701401.).

Topics & Keywords

Hepatitis C virus research Hepatitis B Virus Studies Liver Disease Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 20, pp. 1889-1898

DOI: 10.1056/nejmoa1402454

Field-Weighted Citation Impact: 148.61